Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21273013 | 1.00 | SLC22A6 (0.33) | SLC22A6TDP1SMN1; SMN2ALOX15MAPT | |
| SCHEMBL14261039 | 0.80 | SLC22A6 (0.35) | SLC22A6TDP1SMN1; SMN2ALOX15MAPT | |
| SCHEMBL11261532 | 0.78 | SLC22A6 (0.30) | SLC22A6 | |
| SCHEMBL11357843 | 0.78 | ALDH1A1 (0.30) | SLC22A6 | |
| SCHEMBL26444829 | 0.73 | SLC22A6 (0.36) | SLC22A6TDP1SMN1; SMN2 | |
| SCHEMBL21618444 | 0.72 | — | — | |
| SCHEMBL25242211 | 0.71 | SLC22A6 (0.35) | SLC22A6TDP1SMN1; SMN2 | |
| SCHEMBL11273231 | 0.71 | ADRA1A (0.32) | — | |
| SCHEMBL11268957 | 0.70 | GABRR1 (0.38) | SLC22A6TDP1SMN1; SMN2 | |
| SCHEMBL5184423 | 0.69 | AAK1 (0.36) | SLC22A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4026832-A1 | PIPERIDINE DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | Almac Discovery Limited (GB) | 2022-07-13 | — | — | EP | disclosed |
| US-10766903-B2 | Piperidine derivatives as inhibitors of ubiquitin specific protease 7 | ALMAC DISCOVERY LIMITED (GB) | 2020-09-08 | — | — | US | disclosed |
| US-20190256518-A1 | PIPERIDINE DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | GENETECH, INC. | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190256518-A1 | PIPERIDINE DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | USP7, USP5, UBA7 | SLC22A6 4698/4885TDP1 1878/4885SMN1; SMN2 3429/4885 |
| US-10766903-B2 | Piperidine derivatives as inhibitors of ubiquitin specific protease 7 | USP7, USP5, UBA7 | SLC22A6 4698/4885TDP1 1878/4885SMN1; SMN2 3429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.